RedHill Biopharma (ADR)
Specialty biopharmaceutical developer behind Talicia and a partner-led oral-medicine pipeline.
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability -- Realizes substantial value from RedHill's 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill's transformational commercial expansion -- Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments RALEIGH, N.C. and TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps and potential partnership discussions ongoing, including with the Emergency Task Force expert group of the African Medicines Agency, the Ugandan Ministry of Health and Mbarara University of Science and Technology (MUST), alongside liaison with the Democratic Republic of Congo (DRC) Scientific Advisory Committee -- Professor Pauline Byakika-Kibwika, Vice Chancellor, MUST: "There is an urgent need for additional therapeutic options, and with an oral formulation, ease of administration, human safety database and supportive data, host-directed antiviral opaganib warrants immediate evaluation as a potential treatment candidate for Bundibugyo ebolavirus (BDBV)" -- Development of opaganib for Ebola is supported by preclinical and clinical safety and efficacy data from multiple studies, including in combination with direct acting antiviral Veklury® (remdesivir, Gilead Sciences) TEL AVIV, Israel and RALEIGH, N.C., July 28, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Earnings and Valuation This table
Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200-Day Moving Average – What’s Next?
Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.27 and traded as low as $0.87. Redhill Biopharma shares last traded at $0.8899, with a volume of 7,208 shares traded. Analyst Upgrades and Downgrades Separately,
Redhill Biopharma (NASDAQ:RDHL) Share Price Passes Below 200-Day Moving Average – What’s Next?
Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $1.39 and traded as low as $1.04. Redhill Biopharma shares last traded at $1.06, with a volume of 60,111 shares. Wall Street Analyst
What's Going On With Redhill Biopharma Stock On Tuesday?
Redhill Biopharma Ltd (NASDAQ: RDHL) stock is trading lower on Tuesday, possibly on profit-taking after the stock rallied roughly 36% on Monday, as per data from Benzinga Pro.
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic cells persisting over time, even with combination therapy 1 Studies show that sphingosine kinase 2 (SPHK2) is overexpressed in venetoclax-resistant cancer cells and that SPHK2 inhibition may reduce T-cell-induced activation and proliferation of venetoclax-resistant CLL cancer cells and resensitize previously resistant CLL cells2,3 New in vivo study shows adding opaganib, a potent SPHK2 inhibitor, to venetoclax reduces CLL cell (CD19⁺, CD5⁺) counts by 50% compared to controls and lowered CD3+, CD4+ and CD8+ T cell counts compared to controls with lowered PD1 expression (CD8+) 4 Data shows opaganib's venetoclax combination potential in CLL; builds on multiple preclinical studies demonstrating opaganib's therapeutic add-on potential in oncology; further clinical evaluation ongoing in a Phase 2 study of opaganib + darolutamide in advanced prostate cancer Opaganib has a safety and tolerability profile shown in more than 470 clinical trials / expanded access participants. It targets multiple oncology, virology, inflammation, diabetes and obesity indications, with several U.S. government partnerships, including BARDA funding, in place TEL-AVIV, Israel and RALEIGH, N.C.
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
Critical Review: Redhill Biopharma (NASDAQ:RDHL) and Indaptus Therapeutics (NASDAQ:INDP)
Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk. Profitability This table compares Redhill Biopharma and
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months, plus a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based therapy to address H. pylori antibiotic resistance.
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed Kukbo Co. Ltd's ("Kukbo") defense again, further ruling that RedHill had fulfilled its agreement obligations even after Kukbo's breach RedHill has been granted approximately $10 million in total awards comprised of the $8.25 million original award and a subsequent $1.82 million award for legal costs and expenses (including 9% statutory interest accrual) RALEIGH, N.C., and TEL AVIV, Israel , Sept.
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in the Bayer-supported Phase 2 combination study of opaganib and darolutamide in advanced prostate cancer Positive U.S. Food and Drug Administration (FDA) feedback on pathway to approval for RedHill's next-generation Crohn's disease program with RHB-204 - planned to be the first ever clinical study in a defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population Increased Talicia net revenues and units sold as compared to first half 2024 - achieved with significantly reduced resources Talicia U.S. formulary wins securing 8 million additional covered lives, taking the total to more than 204 million lives UK Marketing Authorization Application (MAA) for Talicia® submission imminent and expected to be in time for potential approval this year Ex-U.S. Talicia: cash inflows from first sales milestone and from royalties, majority received post–balance sheet date Up to $60 million global (ex-North America) RHB-102 out-licensing deal signed with Hyloris Pharmaceuticals Corporate and financial highlights: Gross profit doubled compared to first half 2024 59% increase in net revenues in first half of 2025 to $ 4.1 million, up from $2.6 million in first half of 2024 Enhanced financial stability with up to approximately $13.5 million available to the Company through At-the-Market ("ATM") and Any Market Purchase agreements Cash balance of $3 million as of June 30, 2025 1 Further 19% reduction in cash burn following the previous year's 74% reduction Net cash used in operations in first half of 2025 dropped to $5 million from $6.2 million in first half of 2024 Following RedHill's approximately $8.25 million including interest New York Supreme Court summary judgment win against Kukbo (appeal to be heard this month), the Court also awarded RedHill approximately $1.82 million including interest in legal costs and expenses. RedHill also won an attachment grant in the Korean courts, preventing Kukbo asset disposal prior to enforcement TEL AVIV, Israel and RALEIGH, N.C.
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
The New York Supreme Court has awarded RedHill approximately $1.82 million in legal costs and expenses following, and in addition to, the Court's prior summary judgment of approximately $8.25 million in favor of RedHill in its action against Kukbo Co. Ltd's ("Kukbo"); the $8.25 million and $1.82 million awards include 9% ongoing statutory interest accrual RALEIGH, N.C. and TEL-AVIV, Israel , Aug. 20, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S. commercial launch of Talicia in 2024 Talicia is the first FDA-approved rifabutin-based product specifically designed to treat Helicobacter pylori (H. pylori), a bacterial infection with high and rising resistance rates that affects over 50% of the world's adult population [1] and is the strongest risk factor for gastric cancer and peptic ulcer disease Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists [2] for treatment of H.
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population Groundbreaking approach testing MAP as a root cause of CD, supporting RHB-204 as a potential paradigm-shifting therapy treating both the suspected cause of Crohn's disease and its symptoms RedHill has initiated two new collaborations with leading academic centers utilizing cutting-edge rapid and accurate MAP detection diagnostics – the lack of which has previously been a major barrier to advancing the Company's novel anti-MAP Crohn's disease program Innovative design enables a smaller sample size allowing for lower study costs and faster time to completion Funding for this ground-breaking program expected to be non-dilutive; Grant application submitted and discussions ongoing for additional non-dilutive financing Patent protected through 2041, orally-administered RHB-204, a next-generation optimized formulation of RedHill's RHB-104 designed to further enhance tolerability, safety and patient adherence, is supported by positive RHB-104[2] Phase 3 safety and efficacy results, which delivered a statistically significant 64% improvement in efficacy[3] Expected transferal of pediatric orphan drug designation to RHB-204 as well as potential for breakthrough therapy designation, fast track designation, additional regulatory exclusivity and priority review voucher The multibillion-dollar Crohn's disease market is expected to expand significantly, with sales in the key markets growing from $13.6 billion in 2024 to over $19 billion in 2033[4], presenting significant commercial potential for new, paradigm changing, FDA-approved therapies RALEIGH, N.C. and TEL AVIV, Israel , July 21, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation Precision medicine approach: The 60-patient Phase 2 study uses the PCPro™ lipid biomarker test to identify patients with poor prognosis most likely to benefit from the combination Led by Professor Lisa Horvath, the study is expected to recruit people at sites across Australia and New Zealand Prostate cancer is the second most diagnosed cancer in the world with around 1.5 million new cases per year, causing almost 400,000 deaths 1 . Prostate cancer market is approximately $12 billion 2 This study marks a key step in RedHill's development of opaganib in oncology, complementing its U.S. Government-supported medical countermeasures and infectious diseases programs TEL AVIV, Israel and RALEIGH, N.C.
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement , following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's counterclaims -- Latest Court victory demonstrates RedHill's commitment to collection of the court-mandated award, upon which 9% interest continues to be accruable RALEIGH, N.C. and TEL-AVIV, Israel , May 13, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes -- The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting -- H.
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants This patent grant enhances RedHill's strategic positioning in the global COVID-19 therapeutic space, a market still expected to be worth more than $3 billion in 2025[1] , and expands its patent footprint in Asia, a key pharmaceutical market RHB-107 successfully met the primary endpoint of safety and tolerability, delivering promising reduction in hospitalization efficacy results in a U.S. Phase 2 COVID-19 study[2] . Additional clinical data expected from the externally non-dilutive funded PROTECT study, supported by the U.S. Department of Defense RHB-107 is a novel, patient-friendly oral, once-daily, host-directed potential broad-acting antiviral expected to act independently of viral spike protein mutations [3] RALEIGH, N.C.
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global licensing deal (excluding North America) with Hyloris Pharmaceuticals with RHB-102 for up to $60 million in potential milestone payments Approximately $8 million plus legal costs NY Supreme Court summary judgment win against Kukbo Bayer-supported Phase 2 combination study of opaganib and Bayer's darolutamide in prostate cancer initiated Talicia ® advancement and geographic expansion: Planned UK MAA with potential for approval in 2025 Commercially launched in the United Arab Emirates (UAE) Formulary wins securing 25 million covered lives First-line therapy listing in the recently updated ACG Guideline Advancing next-generation development, RHB-204, into the first ever Phase 2 clinical study in Crohn's Disease (CD) patients who are all MAP-positive, supported by RHB-104's positive Phase 3 data showing a statistically significant 64% improvement in efficacy; FDA path to approval guidance expected in coming weeks Positive results from new U.S. Government funded program for gastrointestinal Acute Radiation Syndrome (GI-ARS) further confirm opaganib's nuclear radiation protective activity.